See more : Kairos Acquisition Corp. (KAIRW) Income Statement Analysis – Financial Results
Complete financial analysis of Elevation Oncology, Inc. (ELEV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elevation Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mapletree Pan Asia Commercial Trust (MPCMF) Income Statement Analysis – Financial Results
- Garibaldi Resources Corp. (GGI.V) Income Statement Analysis – Financial Results
- VP Bank AG (VPBN.SW) Income Statement Analysis – Financial Results
- Daicel Corporation (4202.T) Income Statement Analysis – Financial Results
- Shenzhen JT Automation Equipment Co.,Ltd (300400.SZ) Income Statement Analysis – Financial Results
Elevation Oncology, Inc. (ELEV)
About Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.00K | 27.00K | 18.00K | 15.00K | 0.00 |
| Gross Profit | -39.00K | -27.00K | -18.00K | -15.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.43M | 78.72M | 23.60M | 15.48M | 5.34M |
| General & Administrative | 14.90M | 15.83M | 8.45M | 1.80M | 816.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 543.18K |
| SG&A | 14.90M | 15.83M | 8.45M | 1.80M | 544.00K |
| Other Expenses | 5.11M | -506.00K | 7.00K | 11.00K | 0.00 |
| Operating Expenses | 45.45M | 94.55M | 32.05M | 17.28M | 5.88M |
| Cost & Expenses | 45.45M | 94.55M | 32.05M | 17.28M | 5.88M |
| Interest Income | 3.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.17M | 479.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 39.00K | 27.00K | 18.00K | 15.00K | 3.57M |
| EBITDA | -41.47M | -94.52M | -32.03M | -17.25M | -5.88M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.45M | -94.55M | -32.05M | -17.28M | -5.88M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -229.00K | -506.00K | 7.00K | 11.00K | 0.00 |
| Income Before Tax | -45.67M | -95.06M | -32.04M | -17.27M | -5.88M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 30.00K | 25.00K | -218.56K | -191.30K | -8.82K |
| Net Income | -45.70M | -95.08M | -32.04M | -17.27M | -5.88M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.34 | -4.09 | -1.38 | -0.73 | -0.25 |
| EPS Diluted | -1.34 | -4.09 | -1.38 | -0.73 | -0.25 |
| Weighted Avg Shares Out | 34.08M | 23.27M | 23.21M | 23.76M | 23.76M |
| Weighted Avg Shares Out (Dil) | 34.08M | 23.27M | 23.21M | 23.76M | 23.76M |
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ) cancer – -- On-track to initiate dosing in combination portion of the ongoing Phase 1 clinical...
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
BOSTON , Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs,...
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Progressed into dose expansion portion of Phase 1 trial;...
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock
Elevation Oncology (ELEV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Empery Asset Management's Strategic Acquisition in Elevation Oncology
On September 30, 2024, Empery Asset Management, LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 4,000,000 shares of Elevation Oncology Inc (ELEV, Financial). This transaction, executed at a price of $0.5999 per share, represents a...
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
BOSTON , Sept. 23, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs,...
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BOSTON , Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today...
Undercovered Dozen: Elevation Oncology, Ivanhoe Mines, Union Pacific, Golub Capital +
We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. A take on Easterly Government Properties suggests they offer reliable income similar to Treasury bonds with lower reinvestment risk. Bunge Global is seen as...
Why Is Penny Stock Elevation Oncology Trading Lower On Tuesday?
The stock of Elevation Oncology Inc. ELEV is trading lower on Tuesday after the company reported initial data from the dose escalation portion of the ongoing Phase 1 trial of EO-3021 in patients with advanced, unresectable, or metastatic solid tumors...
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1...
Source: https://incomestatements.info
Category: Stock Reports